Reactivation of hepatitis B virus in a patient with adult T‐cell leukemia–lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab. Issue 3 (18th April 2013)

• Record Type: Journal Article
• Authors: Nakano, Nobuaki; Kusumoto, Shigeru; Tanaka, Yasuhito; Ishida, Takashi; Takeuchi, Shogo; Takatsuka, Yoshifusa; Akinaga, Shiro; Mizokami, Masashi; Ueda, Ryuzo; Utsunomiya, Atae
• Is Part Of: Hepatology research. Volume 44:Issue 3(2014:Mar.)
• Page Start: 354
• Page End: 357
• Publication Date: 2013-04-18
• Subjects: Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12117
• Languages: English
• ISSNs: 1386-6346

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The introduction of molecularly targeted drugs has increased the risk of reactivation of hepatitis B virus (HBV), which is a potentially fatal complication following anticancer chemotherapy even in patients who have previously resolved their HBV infection. CC chemokine receptor 4 (CCR4) has been identified as a novel molecular target in antibody therapy for patients with adult T‐cell leukemia–lymphoma (ATL) and peripheral T‐cell lymphoma, and the humanized anti‐CCR4 monoclonal antibody mogamulizumab has been developed. We reported HBV reactivation of an ATL patient with previously resolved HBV infection after mogamulizumab treatment in a dose‐finding study for this antibody. Our retrospective analysis using preserved samples also revealed the detailed kinetics of HBV DNA levels before and just after HBV reactivation.</p> </abstract>